How to buy Incyte Corporation (INCY) shares in Australia
Learn how to easily invest in Incyte Corporation shares.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Incyte Corporation (INCY) is a leading biotechnology business with stocks listed in the US. It opened the day at US$68.77 after a previous close of US$66.74. During the day the price has varied from a low of USD67.92 to a high of USD70.58. The latest price was USD68.38 (25 minute delay). Incyte Corporation is listed on the NASDAQ. All prices are listed in US Dollars.
How to buy shares in Incyte Corporation
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Incyte Corporation. Find the share by name or ticker symbol: INCY. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Incyte Corporation reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$66.74, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Incyte Corporation, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Incyte Corporation. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- Incyte Corporation key stats
- Compare share trading platforms
- Is Incyte Corporation stock a buy or sell?
- Incyte Corporation performance over time
- Is Incyte Corporation suitable for ethical investing?
- Are Incyte Corporation shares over-valued?
- Incyte Corporation's financials
- How volatile are Incyte Corporation shares?
- Does Incyte Corporation pay a dividend?
- Have Incyte Corporation shares ever split?
- Other common questions
Incyte Corporation stock price (NASDAQ:INCY)Use our graph to track the performance of INCY stocks over time.
Incyte Corporation shares at a glance
|52-week range||US$61.91 - US$101.47|
|50-day moving average||US$66.8792|
|200-day moving average||US$76.9345|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||US$2.412|
Where to buy Incyte Corporation stock
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy Incyte Corporation stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Considering buying Incyte Corporation shares?Before you consider Incyte Corporation, you'll want to hear this.
Ticker Nerd uses advanced software to track hundreds of signals and data points to find stocks before they blow up. You can get the next two hot stocks they find sent to your inbox for free.
Show me how
Incyte Corporation price performance over time
|1 week (2021-11-22)||7.96%|
|3 months (2021-08-27)||-9.65%|
|6 months (2021-05-28)||-18.38%|
|1 year (2020-11-27)||-17.86%|
|2 years (2019-11-29)||-27.38%|
|3 years (2018-11-29)||5.54%|
|5 years (2016-11-29)||-34.92%|
Stocks similar to Incyte Corporation
Is Incyte Corporation under- or over-valued?
Valuing Incyte Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Incyte Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Incyte Corporation's P/E ratio
Incyte Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 28x. In other words, Incyte Corporation shares trade at around 28x recent earnings.
That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).
Incyte Corporation's PEG ratio
Incyte Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.9078. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Incyte Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Incyte Corporation's EBITDA
Incyte Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$713.3 million (£0.0 million).
The EBITDA is a measure of a Incyte Corporation's overall financial performance and is widely used to measure a its profitability.
Incyte Corporation financials
|Revenue TTM||US$2.9 billion|
|Operating margin TTM||22.47%|
|Gross profit TTM||US$276.6 million|
|Return on assets TTM||10.9%|
|Return on equity TTM||19.3%|
|Market capitalisation||US$15.1 billion|
TTM: trailing 12 months
Incyte Corporation's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Incyte Corporation.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Incyte Corporation's total ESG risk score
Total ESG risk: 29.4
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Incyte Corporation's overall score of 29.4 (as at 12/31/2018) is nothing to write home about – landing it in it in the 48th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Incyte Corporation is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Incyte Corporation's environmental score
Environmental score: 7.61/100
Incyte Corporation's environmental score of 7.61 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Incyte Corporation is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Incyte Corporation's social score
Social score: 24.73/100
Incyte Corporation's social score of 24.73 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Incyte Corporation is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Incyte Corporation's governance score
Governance score: 12.56/100
Incyte Corporation's governance score puts it squarely in the 8th percentile of companies rated in the same sector. That could suggest that Incyte Corporation is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Incyte Corporation's controversy score
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Incyte Corporation scored a 1 out of 5 for controversy – the highest score possible, reflecting that Incyte Corporation has managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||29.4|
|Total ESG percentile||47.86|
|Environmental score percentile||8|
|Social score percentile||8|
|Governance score percentile||8|
|Level of controversy||1|
Incyte Corporation share dividends
We're not expecting Incyte Corporation to pay a dividend over the next 12 months.
Have Incyte Corporation's shares ever split?
Incyte Corporation's shares were split on a 2:1 basis on 31 August 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Incyte Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Incyte Corporation shares which in turn could have impacted Incyte Corporation's share price.
Incyte Corporation share price volatility
Over the last 12 months, Incyte Corporation's shares have ranged in value from as little as US$61.91 up to US$101.47. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Incyte Corporation's is 0.7532. This would suggest that Incyte Corporation's shares are less volatile than average (for this exchange).
Incyte Corporation overview
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Incyte Corporation in the news
7 Stocks 'On Sale' This Holiday Season
Incyte Corp. stock outperforms competitors on strong trading day
Pandemic Winner Pfizer Is About To Have Its Best Year Ever Due To COVID
Frequently asked questions
More guides on Finder
The latest Cathay Pacific companion sale lets you fly from $1,298 return
Two are better than one with this Black Friday deal to destinations worldwide.
Black Friday 2021: The 15 best deals from Bally
Save up to 40% on quality leather goods and fashionable items from some of Bally's biggest sellers.
Huge Black Friday deal: 120GB for only $30 a month
This is a steal of a deal.
The best Black Friday 2021 flight deals in Australia
It's the best time to use up your banked up annual leave.
5 Black Friday points offers to know about before shopping Cyber Weekend
Points hackers, get your frequent flyer cards ready.
Get $162 off Nintendo Switch bundles this Black Friday
Get the Nintendo Switch bundled with Mario Kart 8 Deluxe and a 3-month Nintendo Switch Online subscription for $369 - save $160!
Today’s ASX top stocks: Australian Finance Group (AFG ↑6.8%), Maas Group Holdings (MGH ↑6.4%)
The 10 biggest movers on the ASX for Friday 26 November 2021.
What is weighing down the AMP share price today?
Shares in the beleaguered financial services giant have dropped more than 10% in the last month alone.
6 Australian Black Friday deals you need to know about
From Apple AirPods to your own Baby Yoda, these are 6 deals you don't want to miss on Black Friday.
How to set up recurring trades in your Finder Wallet
See how you can auto-invest in crypto by using the Finder Wallet recurring trade feature.
Ask an Expert